261 related articles for article (PubMed ID: 30157178)
1. CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.
Byrne G; O'Rourke SM; Alexander DL; Yu B; Doran RC; Wright M; Chen Q; Azadi P; Berman PW
PLoS Biol; 2018 Aug; 16(8):e2005817. PubMed ID: 30157178
[TBL] [Abstract][Full Text] [Related]
2. Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens.
Li SW; Wright M; Healey JF; Hutchinson JM; O'Rourke S; Mesa KA; Lollar P; Berman PW
PLoS One; 2020; 15(5):e0233866. PubMed ID: 32470085
[TBL] [Abstract][Full Text] [Related]
3. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
[TBL] [Abstract][Full Text] [Related]
4. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
[TBL] [Abstract][Full Text] [Related]
5. Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production.
O'Rourke SM; Byrne G; Tatsuno G; Wright M; Yu B; Mesa KA; Doran RC; Alexander D; Berman PW
PLoS One; 2018; 13(8):e0197656. PubMed ID: 30071025
[TBL] [Abstract][Full Text] [Related]
6. Development of a Stable MGAT1
Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW
Front Immunol; 2018; 9():2313. PubMed ID: 30344523
[TBL] [Abstract][Full Text] [Related]
7. Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.
Li SW; Yu B; Byrne G; Wright M; O'Rourke S; Mesa K; Berman PW
Biotechnol Bioeng; 2019 Sep; 116(9):2130-2145. PubMed ID: 31087560
[TBL] [Abstract][Full Text] [Related]
8. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
J Virol; 2017 May; 91(9):. PubMed ID: 28202756
[TBL] [Abstract][Full Text] [Related]
10. Engineering Chinese hamster ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)-mediated gene knockout of mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat1).
Sealover NR; Davis AM; Brooks JK; George HJ; Kayser KJ; Lin N
J Biotechnol; 2013 Aug; 167(1):24-32. PubMed ID: 23777858
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
Morales JF; Morin TJ; Yu B; Tatsuno GP; O'Rourke SM; Theolis R; Mesa KA; Berman PW
J Biol Chem; 2014 Jul; 289(30):20526-42. PubMed ID: 24872420
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
[TBL] [Abstract][Full Text] [Related]
13. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
Wu Z; Kayman SC; Honnen W; Revesz K; Chen H; Vijh-Warrier S; Tilley SA; McKeating J; Shotton C; Pinter A
J Virol; 1995 Apr; 69(4):2271-8. PubMed ID: 7533854
[TBL] [Abstract][Full Text] [Related]
14. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
Yu B; Morales JF; O'Rourke SM; Tatsuno GP; Berman PW
PLoS One; 2012; 7(8):e43903. PubMed ID: 22928048
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
16. Application of the CRISPR/Cas9 Gene Editing Method for Modulating Antibody Fucosylation in CHO Cells.
Wang Q; Chung CY; Rosenberg JN; Yu G; Betenbaugh MJ
Methods Mol Biol; 2018; 1850():237-257. PubMed ID: 30242691
[TBL] [Abstract][Full Text] [Related]
17. Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.
Zambonelli C; Dey AK; Hilt S; Stephenson S; Go EP; Clark DF; Wininger M; Labranche C; Montefiori D; Liao HX; Swanstrom RI; Desaire H; Haynes BF; Carfi A; Barnett SW
PLoS One; 2016; 11(7):e0157391. PubMed ID: 27442017
[TBL] [Abstract][Full Text] [Related]
18. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins.
Go EP; Liao HX; Alam SM; Hua D; Haynes BF; Desaire H
J Proteome Res; 2013 Mar; 12(3):1223-34. PubMed ID: 23339644
[TBL] [Abstract][Full Text] [Related]
19. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
